Failure of anticoagulant thromboprophylaxis: Risk factors in medical-surgical critically Ill patients

Critical Care Medicine

Volumn 43, Issue 2, 2015, Pages 401-410

  Lim, Wendy ^a   Meade, Maureen ^a   Lauzier, Francois ^b,c   Zarychanski, Ryan ^d   Mehta, Sangeeta ^e   Lamontagne, Francois ^f   Dodek, Peter ^g   McIntyre, Lauralyn ^h   Hall, Richard ⁱ   Heels Ansdell, Diane ^a   Fowler, Robert ^e   Pai, Menaka ^a   Guyatt, Gordon ^a   Crowther, Mark A ^a   Warkentin, Theodore E ^a   Devereaux, P J ^a   Walter, Stephen D ^a   Muscedere, John ^j   Herridge, Margaret ^e   Turgeon, Alexis F ^b,k   Geerts, William ^e   Finfer, Simon ^l,m   Jacka, Michael ⁿ   Berwanger, Otavio ^o   Ostermann, Marlies ^p   Qushmaq, Ismael ^q   Friedrich, Jan O ^e   Cook, Deborah J ^a   more..

^a MCMASTER UNIVERSITY   (Canada)

^b University Laval   (Canada)

^c Department of Medicine Division of Critical Care   (Canada)

^d UNIVERSITY OF MANITOBA   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f UNIVERSITÉ DE SHERBROOKE   (Canada)

^g ST PAUL S HOSPITAL   (Canada)

^h UNIVERSITY OF OTTAWA   (Canada)

ⁱ QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^j QUEEN S UNIVERSITY   (Canada)

^k Department of Anesthesia Queen Elizabeth II Health Sciences Centre ^*  (Canada)

^l ROYAL NORTH SHORE HOSPITAL   (Australia)

^m UNIVERSITY OF SYDNEY   (Australia)

ⁿ UNIVERSITY OF ALBERTA   (Canada)

^o Hospital do Coração Associação do Sanatório Sírio   (Brazil)

^p GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^q KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

more..

Author keywords

Anticoagulant; Critically ill; Heparin; Intensive care unit; Low molecular weight heparin; Thromboprophylaxis

Indexed keywords

DALTEPARIN; HEPARIN; ANTICOAGULANT AGENT;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DRUG TREATMENT FAILURE; FEMALE; HUMAN; INTENSIVE CARE UNIT; LEG THROMBOSIS; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SENSITIVITY ANALYSIS; THROMBOPROPHYLAXIS; VENOUS THROMBOEMBOLISM; AGE; AGED; APACHE; CHEMOPROPHYLAXIS; CLINICAL PROTOCOL; CLINICAL TRIAL; CRITICAL ILLNESS; MIDDLE AGED; PULMONARY EMBOLISM; STATISTICS AND NUMERICAL DATA; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; APACHE; BODY MASS INDEX; CHEMOPREVENTION; CLINICAL PROTOCOLS; CRITICAL ILLNESS; FEMALE; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; PULMONARY EMBOLISM; RISK FACTORS; VENOUS THROMBOEMBOLISM;

EID: 84925351608     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0000000000000713     Document Type: Article

References (36)

1. Kahn SR, Lim W, Dunn AS, et al; American College of Chest Physicians: Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141(2 Suppl):195-226.
2. Levi M, van der Poll T: Inflammation and coagulation. Crit Care Med 2010; 38:26-34.
3. Cook DJ, Meade M, Guyatt G, et al; for the PROTECT (Prophylaxis for ThromboEmbolism in Critical Care Trial) Investigators for the Canadian Critical Care Trials Group & the Australian and New Zealand Intensive Care Society Clinical Trials Group: Dalteparin versus unfractionated heparin in critically ill patients. N Engl J Med 2011; 364:1305-1314.
4. Shorr AF, Williams MD: Venous thromboembolism in critically ill patients. Observations from a randomized trial in sepsis. Thromb Haemost 2009; 101:139-144.
5. Cook D, Crowther M, Meade M, et al: Deep venous thrombosis in medical-surgical critically ill patients: Prevalence, incidence, and risk factors. Crit Care Med 2005; 33:1565-1571.
6. Cook D, Douketis J, Meade M, et al; Canadian Critical Care Trials Group: Venous thromboembolism and bleeding in critically ill patients with severe renal insufficiency receiving dalteparin thromboprophylaxis: Prevalence, incidence and risk factors. Crit Care 2008; 12:32.
7. Ibrahim EH, Iregui M, Prentice D, et al: Deep vein thrombosis during prolonged mechanical ventilation despite prophylaxis. Crit Care Med 2002; 30:771-774.
8. Kollef MH, Eisenberg PR, Shannon W: A rapid assay for the detection of circulating D-dimer is associated with clinical outcomes among critically ill patients. Crit Care Med 1998; 26:1054-1060.
9. Minet C, Lugosi M, Savoye PY, et al: Pulmonary embolism in mechanically ventilated patients requiring computed tomography: Prevalence, risk factors, and outcome. Crit Care Med 2012; 40:3202-3208.
10. Zarychanski R, Turgeon AF, McIntyre L, et al: Erythropoietin-receptor agonists in critically ill patients: A meta-analysis of randomized controlled trials. CMAJ 2007; 177:725-734.
11. Glynn RJ, Danielson E, Fonseca FA, et al: A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 2009; 360:1851-1861.
12. Cook DJ, Meade M, Guyatt G, et al; for the PROTECT Investigators, the Canadian Critical Care Trials Group and the Australian and New Zealand Intensive Care Society Clinical Trials Group: PROphylaxis for ThromboEmbolism in Critical Care Trial protocol and analysis plan. J Crit Care 2011; 26:223.1-223.e9.
13. Cox DR: Regression models and life tables. J R Stat Soc 1972; 34:187-220.
14. Knaus WA, Draper EA, Wagner DP, et al: APACHE II: A severity of disease classification system. Crit Care Med 1985; 13:818-829.
15. Babyak MA: What you see may not be what you get: A brief, nontechnical introduction to overfitting in regression-type models. Psychosom Med 2004; 66:411-421.
16. Warkentin TE, Hayward CP, Smith CA, et al: Determinants of donor platelet variability when testing for heparin-induced thrombocytopenia. J Lab Clin Med 1992; 120:371-379.
17. Severinsen MT, Kristensen SR, Johnsen SP, et al: Anthropometry, body fat, and venous thromboembolism: A Danish follow-up study. Circulation 2009; 120:1850-1857.
18. Ageno W, Becattini C, Brighton T, et al: Cardiovascular risk factors and venous thromboembolism: A meta-analysis. Circulation 2008; 117:93-102.
19. Raschke RA, Reilly BM, Guidry JR, et al: The weight-based heparin dosing nomogram compared with a "standard care" nomogram. A randomized controlled trial. Ann Intern Med 1993; 119:874-881.
20. Connolly SJ, Ezekowitz MD, Yusuf S, et al; RE-LY Steering Committee and Investigators: Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361:1139-1151.
21. Houston DS, Zarychanski R: Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361:2671; author reply 2674-2675.
22. Patel MR, Mahaffey KW, Garg J, et al; ROCKET AF Investigators: Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365:883-891.
23. Malinoski D, Jafari F, Ewing T, et al: Standard prophylactic enoxaparin dosing leads to inadequate anti-Xa levels and increased deep venous thrombosis rates in critically ill trauma and surgical patients. J Trauma 2010; 68:874-880.
24. Robinson S, Zincuk A, Larsen UL, et al: A comparative study of varying doses of enoxaparin for thromboprophylaxis in critically ill patients: A double-blinded, randomised controlled trial. Crit Care 2013; 17:75.
25. Ludwig KP, Simons HJ, Mone M, et al: Implementation of an enoxaparin protocol for venous thromboembolism prophylaxis in obese surgical intensive care unit patients. Ann Pharmacother 2011; 45:1356-1362.
26. Freeman A, Horner T, Pendleton RC, et al: Prospective comparison of three enoxaparin dosing regimens to achieve target anti-factor Xa levels in hospitalized, medically ill patients with extreme obesity. Am J Hematol 2012; 87:740-743.
27. Rondina MT, Wheeler M, Rodgers GM, et al: Weight-based dosing of enoxaparin for VTE prophylaxis in morbidly obese, medically-Ill patients. Thromb Res 2010; 125:220-223.
28. Zöller B, Li X, Sundquist J, et al: Age- And gender-specific familial risks for venous thromboembolism: A nationwide epidemiological study based on hospitalizations in Sweden. Circulation 2011; 124:1012-1020.
29. Dörffler-Melly J, de Jonge E, Pont AC, et al: Bioavailability of subcutaneous low-molecular-weight heparin to patients on vasopressors. Lancet 2002; 359:849-850.
30. Pai M, Evans NS, Shah SJ, et al: Statins in the prevention of venous thromboembolism: A meta-analysis of observational studies. Thromb Res 2011; 128:422-430.
31. Crowther MA, Cook DJ, Griffith LE, et al: Neither baseline tests of molecular hypercoagulability nor D-dimer levels predict deep venous thrombosis in critically ill medical-surgical patients. Intensive Care Med 2005; 31:48-55.
32. Lamontage F, McIntyre L, Dodek P, et al. Non-leg venous thrombosis in critically ill adults: A nested prospective cohort study. JAMA Intern Med 2014; 174:689-696.
33. Warkentin TE, Roberts RS, Hirsh J, et al: An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern Med 2003; 163:2518-2524.
34. Warkentin TE: HITlights: A career perspective on heparin-induced thrombocytopenia. Am J Hematol 2012; 87(Suppl 1):92-99.
35. Crowther MA, Cook DJ, Griffith LE, et al: Deep venous thrombosis: Clinically silent in the intensive care unit. J Crit Care 2005; 20:334-340.
36. Dooley C, Kaur R, Sobieraj DM: Comparison of the efficacy and safety of low molecular weight heparins for venous thromboembolism prophylaxis in medically ill patients. Curr Med Res Opin 2014; 30:367-380.